Pedro Granadillo Net Worth

The estimated Net Worth of Pedro P Granadillo is at least $5.89 Million dollars as of 8 November 2018. Mr. Granadillo owns over 12,322 units of Rocket Pharmaceuticals Inc stock worth over $291,825 and over the last 20 years he sold RCKT stock worth over $5,255,016. In addition, he makes $338,545 as Independent Director at Rocket Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Granadillo RCKT stock SEC Form 4 insiders trading

Pedro has made over 17 trades of the Rocket Pharmaceuticals Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he sold 12,322 units of RCKT stock worth $1,410,869 on 8 November 2018.

The largest trade he's ever made was selling 30,824 units of Rocket Pharmaceuticals Inc stock on 17 September 2018 worth over $3,447,048. On average, Pedro trades about 3,581 units every 134 days since 2004. As of 8 November 2018 he still owns at least 15,335 units of Rocket Pharmaceuticals Inc stock.

You can see the complete history of Mr. Granadillo stock trades at the bottom of the page.

Pedro Granadillo biography

Pedro Granadillo serves as Independent Director of the Company. He has over 40 years of biopharmaceutical industry experience with expertise in human resources, manufacturing, quality and corporate governance. From 1970 until his retirement in 2004, Mr. Granadillo held multiple leadership roles at Eli Lilly and Company, including Senior Vice President of Global Manufacturing and Human Resources and a member of the Executive Committee. Mr. Granadillo has previously served on the boards of directors at Haemonetics Corporation, Dendreon Corporation, Health Sciences Acquisitions Corporation and Noven Pharmaceuticals, as well as NPS Pharmaceuticals, which sold to Shire for $5.2 billion in 2015. He graduated from Purdue University with a Bachelor of Science in Industrial Engineering.

What is the salary of Pedro Granadillo?

As the Independent Director of Rocket Pharmaceuticals Inc, the total compensation of Pedro Granadillo at Rocket Pharmaceuticals Inc is $338,545. There are 9 executives at Rocket Pharmaceuticals Inc getting paid more, with Gaurav Shah having the highest compensation of $3,883,650.

How old is Pedro Granadillo?

Pedro Granadillo is 73, he's been the Independent Director of Rocket Pharmaceuticals Inc since 2018. There are no older and 17 younger executives at Rocket Pharmaceuticals Inc.

What's Pedro Granadillo's mailing address?

Pedro's mailing address filed with the SEC is C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY, NJ, 08512.

Insiders trading at Rocket Pharmaceuticals Inc

Over the last 7 years, insiders at Rocket Pharmaceuticals Inc have traded over $45,364,690 worth of Rocket Pharmaceuticals Inc stock and bought 2,407,332 units worth $48,979,646 . The most active insiders traders include Investments, Lpwong Roderic..., Mikael Dolsten, and Investments, Lpwong Roderic.... On average, Rocket Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $1,269,815. The most recent stock trade was executed by John Militello on 16 August 2024, trading 1,064 units of RCKT stock currently worth $19,684.

What does Rocket Pharmaceuticals Inc do?

rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.

Complete history of Mr. Granadillo stock trades at Haemonetics and Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc executives and stock owners

Rocket Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Gaurav Shah,
  President, Chief Executive Officer, Director
• Kinnari Patel,
  Chief Operating Officer and Head of Development
• Kamran Alam,
  Senior Vice President - Finance, Principal Financial Officer
• Jonathan Schwartz,
  Chief Medical Officer
• Dr. Gaurav D. Shah,
  CEO & Director
• Kinnari Patel M.B.A., Pharm.D., PharmD, MBA,
  Pres, COO & Head of Devel.
• Jonathan Schwartz,
  Chief Medical Officer & Sr. VP of Clinical Devel.
• John C. Militello CPA, CPA,
  VP, Sr. Controller & Principal Accounting Officer
• Roderick Wong,
  Chairman of the Board
• Pedro Granadillo,
  Independent Director
• Carsten Boess,
  Independent Director
• Naveen Yalamanchi,
  Independent Director
• Gotham Makker,
  Independent Director
• David Southwell,
  Director
• Elisabeth Bjork,
  Independent Director
• John Militello,
  Principal Accounting Officer and Senior Controller
• Dr. Gayatri R. Rao J.D., M.D.,
  Chief Devel. Officer of LVV & Sr. VP
• Isabel Carmona J.D.,
  Sr. VP & Chief HR Officer
• Kevin Giordano,
  Director of Corp. Communications
• Martin L. Wilson,
  Gen. Counsel, Chief Compliance Officer & Sr. VP
• Mayur Kasetty,
  Bus. Devel. & Operations and Investor Relations Lead
• Carlos Garcia-Parada M.B.A.,
  Chief Financial Officer
• Investments, Lpwong Roderic...,
  
• Mark Andrew White,
  See Remarks
• Investments, Lpwong Roderic...,
  
• Roderickrtw Investments, Lp...,
  
• Keith Woods,
  
• Fady Ibraham Malik,
  
• Carlos Garcia Parada,
  Chief Financial Officer
• Martin Wilson,
  General Counsel
• Mikael Dolsten,
  
• Aaron Ondrey,
  Chief Financial Officer